NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh

NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh

KKRX:950220
1,485.00
KRW
-9.00
(-0.60%)
-527.25EPS
8.82BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
43.2
0.8
37.72
Basic EPS, GAAP
-4,370
-9,205
-13,790
-15,310
-13,510
-10,365
-269.22
-527.25
Free Cash Flow per Basic Share
-4,684.96
-9,065.01
-9,615.9
-11,375.32
-12,788.42
-10,296.21
-273.01
-601.08
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
35,021.27
25,453.72
41,093.31
30,277.33
18,928.47
10,534.77
8,830.32
8,407.92
Tangible Book Value per Share
32,804.65
23,498.28
39,421.98
28,619.47
17,368.86
8,900.91
6,918.43
5,395.12
Basic Weighted Avg Shares
3
3
4
4
4
4
118
46
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
170
95
1,754
Operating Margin (%)
- -
- -
- -
- -
- -
-23,497.6
-26,596.51
-1,200.62
Depreciation Expense
781
988
1,873
2,802
3,210
3,673
2,498
2,475
Net Income, GAAP
-14,198
-30,456
-52,482
-60,406
-53,405
-40,883
-31,796
-24,515
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-23,994.58
-33,531.39
-1,397.95
Working Capital
106,685
71,633
146,311
101,574
59,371
18,550
43,117
33,248
LT Debt
2,375
2,360
4,511
3,572
2,555
2,686
1,934
1,550
Total Equity
115,886
84,227
162,042
119,689
74,856
41,662
59,212
56,380
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-30.44
-42.62
-42.88
-54.9
-70.17
-63.04
-61.2

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
8,558
9,153
9,731
LT Borrowings
- -
- -
- -
LT Finance Leases
1,934
1,757
1,550
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
27,526
17,535
8,824

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
63,804
60,595
51,417
Cash, Cash Equivalents & STI
60,822
57,831
47,275
Accounts Receivable, Net
32
391
1,344
Inventories
- -
- -
620
Total Current Liabilities
20,686
22,894
18,169
Payables & Accruals
- -
- -
- -
ST Debt
8,558
9,153
9,731
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
5.32%
42.13%
Free Cash Flow
- -
3.41%
-20.6%
Net Income, GAAP
- -
6.03%
-22.23%
Sales/Revenue/Turnover
- -
- -
-44.35%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
132
-920
170
2025
13
25
18
39
95
2026
527
1,170
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-2,925
-2,495
-2,705
-2,168.67
-10,365
2025
-2,105
-9,210
-1,340
-63.92
-269.22
2026
-1,170
-59
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Luke Oh
Full Time Employees
40
Sector
Health technology
Industry
Biotechnology
Address
2400 Research Blvd. Rockville MD United States 20850
IPO Date
Mar 16, 2021
Business
NeoImmuneTech, Inc. is a biopharmaceutical firm in clinical development, dedicated to advancing T cell-focused immunotherapeutics. The company primarily concentrates on its leading asset, NT-I7 (efineptakin alfa), an investigational, long-acting human interleukin-7 designed to boost T cell numbers and function across various oncologic and infectious diseases. This innovative approach seeks to enhance the efficacy of existing treatments like checkpoint inhibitors and CAR-T cell therapies in solid tumors, hematologic malignancies, and conditions such as acute radiation syndrome and Progressive Multifocal Leukoencephalopathy. Recent developments include positive Phase 1b data combining NT-I7 with CAR-T for large B-cell lymphoma, demonstrating improved response rates and T-cell persistence, as well as an FDA IND approval for a combination trial with BCMA CAR-T therapy for multiple myeloma. Additionally, NT-I7 has received Orphan Drug Designations for conditions including glioblastoma multiforme, pancreatic cancer, and acute radiation syndrome. Established in 2014, NeoImmuneTech maintains its headquarters in Rockville, Maryland, with operations spanning both the U.S. and Korea.